-DOCSTART- -X- O
A -X- _ O
close -X- _ O
relative -X- _ O
of -X- _ O
poliovirus -X- _ O
, -X- _ O
enterovirus -X- _ O
71 -X- _ O
( -X- _ O
EV71 -X- _ O
) -X- _ O
is -X- _ O
regarded -X- _ O
as -X- _ O
an -X- _ O
important -X- _ O
neurotropic -X- _ O
virus -X- _ O
of -X- _ O
serious -X- _ O
public -X- _ O
health -X- _ O
concern. -X- _ O
EV71 -X- _ O
causes -X- _ O
Hand -X- _ O
, -X- _ O
Foot -X- _ O
and -X- _ O
Mouth -X- _ O
Disease -X- _ O
and -X- _ O
has -X- _ O
been -X- _ O
associated -X- _ O
with -X- _ O
neurological -X- _ O
complications -X- _ O
in -X- _ O
young -X- _ O
children. -X- _ O
Our -X- _ O
limited -X- _ O
understanding -X- _ O
of -X- _ O
the -X- _ O
mechanisms -X- _ O
involved -X- _ O
in -X- _ O
its -X- _ O
neuropathogenesis -X- _ O
has -X- _ O
hampered -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
effective -X- _ O
therapeutic -X- _ O
options. -X- _ O
Here -X- _ O
, -X- _ O
using -X- _ O
a -X- _ O
two-dimensional -X- _ O
proteomics -X- _ O
approach -X- _ O
combined -X- _ O
with -X- _ O
mass -X- _ O
spectrometry -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
identified -X- _ O
a -X- _ O
unique -X- _ O
panel -X- _ O
of -X- _ O
host -X- _ O
proteins -X- _ O
that -X- _ O
were -X- _ O
differentially -X- _ O
and -X- _ O
dynamically -X- _ O
modulated -X- _ O
during -X- _ O
EV71 -X- _ O
infection -X- _ O
of -X- _ O
motor-neuron -X- _ O
NSC-34 -X- _ B-Patient
cells -X- _ I-Patient
, -X- _ O
which -X- _ O
are -X- _ O
found -X- _ O
at -X- _ O
the -X- _ O
neuromuscular -X- _ O
junctions -X- _ O
where -X- _ O
EV71 -X- _ O
is -X- _ O
believed -X- _ O
to -X- _ O
enter -X- _ O
the -X- _ O
central -X- _ O
nervous -X- _ O
system. -X- _ O
Meta-analysis -X- _ O
with -X- _ O
previously -X- _ O
published -X- _ O
proteomics -X- _ O
studies -X- _ O
in -X- _ O
neuroblastoma -X- _ O
or -X- _ O
muscle -X- _ O
cell -X- _ O
lines -X- _ O
revealed -X- _ O
minimal -X- _ O
overlapping -X- _ O
which -X- _ O
suggests -X- _ O
unique -X- _ O
host-pathogen -X- _ O
interactions -X- _ O
in -X- _ O
NSC-34 -X- _ B-Patient
cells. -X- _ I-Patient
Among -X- _ O
the -X- _ O
candidate -X- _ O
proteins -X- _ O
, -X- _ O
we -X- _ O
focused -X- _ O
our -X- _ O
attention -X- _ O
on -X- _ O
prohibitin -X- _ O
( -X- _ O
PHB -X- _ O
) -X- _ O
, -X- _ O
a -X- _ O
protein -X- _ O
that -X- _ O
is -X- _ O
involved -X- _ O
in -X- _ O
multiple -X- _ O
cellular -X- _ O
functions -X- _ O
and -X- _ O
the -X- _ O
target -X- _ O
of -X- _ O
anti-cancer -X- _ O
drug -X- _ O
Rocaglamide -X- _ O
( -X- _ O
Roc-A -X- _ O
) -X- _ O
. -X- _ O
We -X- _ O
demonstrated -X- _ O
that -X- _ O
cell -X- _ O
surface-expressed -X- _ O
PHB -X- _ O
is -X- _ O
involved -X- _ O
in -X- _ O
EV71 -X- _ O
entry -X- _ O
into -X- _ O
neuronal -X- _ O
cells -X- _ O
specifically -X- _ O
, -X- _ O
while -X- _ O
membrane-bound -X- _ O
mitochondrial -X- _ O
PHB -X- _ O
associates -X- _ O
with -X- _ O
the -X- _ O
virus -X- _ O
replication -X- _ O
complex -X- _ O
and -X- _ O
facilitates -X- _ O
viral -X- _ O
replication. -X- _ O
Furthermore -X- _ O
, -X- _ O
Roc-A -X- _ B-Intervention
treatment -X- _ I-Intervention
of -X- _ O
EV71-infected -X- _ B-Intervention
neuronal -X- _ I-Intervention
cells -X- _ I-Intervention
reduced -X- _ O
significantly -X- _ O
virus -X- _ O
yields. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
inhibitory -X- _ O
effect -X- _ O
of -X- _ O
Roc-A -X- _ O
on -X- _ O
PHB -X- _ O
in -X- _ O
NSC-34 -X- _ B-Patient
cells -X- _ I-Patient
was -X- _ O
not -X- _ O
through -X- _ O
blocking -X- _ O
the -X- _ O
CRAF -X- _ O
/ -X- _ O
MEK -X- _ O
/ -X- _ O
ERK -X- _ O
pathway -X- _ O
as -X- _ O
previously -X- _ O
reported. -X- _ O
Instead -X- _ O
, -X- _ O
Roc-A -X- _ O
treated -X- _ O
NSC-34 -X- _ B-Patient
cells -X- _ I-Patient
had -X- _ O
lower -X- _ O
mitochondria-associated -X- _ O
PHB -X- _ O
and -X- _ O
lower -X- _ O
ATP -X- _ O
levels -X- _ O
that -X- _ O
correlated -X- _ O
with -X- _ O
impaired -X- _ O
mitochondria -X- _ O
integrity. -X- _ O
In -X- _ O
vivo -X- _ O
, -X- _ O
EV71-infected -X- _ B-Outcome
mice -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
Roc-A -X- _ I-Outcome
survived -X- _ I-Outcome
longer -X- _ I-Outcome
than -X- _ I-Outcome
the -X- _ I-Outcome
vehicle-treated -X- _ I-Outcome
animals -X- _ I-Outcome
and -X- _ I-Outcome
had -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
virus -X- _ I-Outcome
loads -X- _ I-Outcome
in -X- _ I-Outcome
their -X- _ I-Outcome
spinal -X- _ I-Outcome
cord -X- _ I-Outcome
and -X- _ I-Outcome
brain -X- _ I-Outcome
, -X- _ I-Outcome
whereas -X- _ I-Outcome
virus -X- _ I-Outcome
titers -X- _ I-Outcome
in -X- _ I-Outcome
their -X- _ I-Outcome
limb -X- _ I-Outcome
muscles -X- _ I-Outcome
were -X- _ I-Outcome
comparable -X- _ I-Outcome
to -X- _ I-Outcome
controls. -X- _ I-Outcome
Together -X- _ O
, -X- _ O
this -X- _ O
study -X- _ O
uncovers -X- _ O
PHB -X- _ O
as -X- _ O
the -X- _ O
first -X- _ O
host -X- _ O
factor -X- _ O
that -X- _ O
is -X- _ O
specifically -X- _ O
involved -X- _ O
in -X- _ O
EV71 -X- _ O
neuropathogenesis -X- _ O
and -X- _ O
a -X- _ O
potential -X- _ O
drug -X- _ O
target -X- _ O
to -X- _ O
limit -X- _ O
neurological -X- _ O
complications -X- _ O
. -X- _ O

